FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014232833> ?p ?o ?g. }

• W3014232833 endingPage "S322" @default.
• W3014232833 startingPage "S322" @default.
• W3014232833 abstract "Purpose Calcineurin inhibitors (CNI) are the cornerstone of immunosuppression in lung transplantation. The International Heart and Lung Transplant registry data estimates that almost 99% of patients are on a CNI-based immunosuppression regimen. The population of lung transplant (LTx) recipients not on a calcineurin inhibitor is exceedingly rare and their outcomes have not been previously examined in a systematic way. Methods An IRB-approved, retrospective, observational, cohort study of LTx recipients who received CNI-free, everolimus (EVR)-based immunosuppression at the University of Colorado from January 1, 1995 - October 1, 2019. The health system's electronic medical records was queried to identify and collect data on eligible LTx recipients. All continuous variables are presented as median(range). Results Seven of 12 were single LTx (ILD, COPD), five were bilateral LTx,(ILD, COPD, CF) and one was a re-transplant. The majority (8/12) of patients were transitioned to CNI-free, EVR-based immunosuppression due to renal insufficiency, 3/12 due to metastatic cancer, and 1/12 due to both renal failure and cancer. Five of 12 were maintained on three agents (EVR, corticosteroid, and either methotrexate or azathioprine) and the others were on corticosteroids with EVR alone. The median time to transition to CNI-free immunosuppression was 8.8 (2.3 to 21.3) years. Median age at CNI cessation was 67 years old (40-72 years old). Median survival on CNI-free immunosuppression for all comers was 1.6 years with median survival in the deceased cohort (n=8) of 1 year (4 days to 4.6 years) and median survival in the living cohort (n=4) of 2.1 years (1.2 years to 8.2 years). At least three patients were treated with high dose steroids for presumed acute rejection after stopping the CNI. Conclusion This review demonstrates that in certain situations withdrawal of CNI and transition to CNI-free, EVR- based immunosuppression may result in durable patient survival. Larger multicenter cohort analysis may be the next step in understanding the safety, efficacy and role of CNI-free immunosuppression, as equipoise would be impossible to achieve in a randomized controlled trial. Calcineurin inhibitors (CNI) are the cornerstone of immunosuppression in lung transplantation. The International Heart and Lung Transplant registry data estimates that almost 99% of patients are on a CNI-based immunosuppression regimen. The population of lung transplant (LTx) recipients not on a calcineurin inhibitor is exceedingly rare and their outcomes have not been previously examined in a systematic way. An IRB-approved, retrospective, observational, cohort study of LTx recipients who received CNI-free, everolimus (EVR)-based immunosuppression at the University of Colorado from January 1, 1995 - October 1, 2019. The health system's electronic medical records was queried to identify and collect data on eligible LTx recipients. All continuous variables are presented as median(range). Seven of 12 were single LTx (ILD, COPD), five were bilateral LTx,(ILD, COPD, CF) and one was a re-transplant. The majority (8/12) of patients were transitioned to CNI-free, EVR-based immunosuppression due to renal insufficiency, 3/12 due to metastatic cancer, and 1/12 due to both renal failure and cancer. Five of 12 were maintained on three agents (EVR, corticosteroid, and either methotrexate or azathioprine) and the others were on corticosteroids with EVR alone. The median time to transition to CNI-free immunosuppression was 8.8 (2.3 to 21.3) years. Median age at CNI cessation was 67 years old (40-72 years old). Median survival on CNI-free immunosuppression for all comers was 1.6 years with median survival in the deceased cohort (n=8) of 1 year (4 days to 4.6 years) and median survival in the living cohort (n=4) of 2.1 years (1.2 years to 8.2 years). At least three patients were treated with high dose steroids for presumed acute rejection after stopping the CNI. This review demonstrates that in certain situations withdrawal of CNI and transition to CNI-free, EVR- based immunosuppression may result in durable patient survival. Larger multicenter cohort analysis may be the next step in understanding the safety, efficacy and role of CNI-free immunosuppression, as equipoise would be impossible to achieve in a randomized controlled trial." @default.
• W3014232833 created "2020-04-10" @default.
• W3014232833 creator A5000215707 @default.
• W3014232833 creator A5045375491 @default.
• W3014232833 creator A5077451157 @default.
• W3014232833 creator A5079051663 @default.
• W3014232833 date "2020-04-01" @default.
• W3014232833 modified "2023-09-26" @default.
• W3014232833 title "Survival in Lung Transplant Recipients on a Calcineurin Free Regimen: Is It Possible?" @default.
• W3014232833 doi "https://doi.org/10.1016/j.healun.2020.01.726" @default.
• W3014232833 hasPublicationYear "2020" @default.
• W3014232833 type Work @default.
• W3014232833 sameAs 3014232833 @default.
• W3014232833 citedByCount "1" @default.
• W3014232833 countsByYear W30142328332023 @default.
• W3014232833 crossrefType "journal-article" @default.
• W3014232833 hasAuthorship W3014232833A5000215707 @default.
• W3014232833 hasAuthorship W3014232833A5045375491 @default.
• W3014232833 hasAuthorship W3014232833A5077451157 @default.
• W3014232833 hasAuthorship W3014232833A5079051663 @default.
• W3014232833 hasConcept C119060515 @default.
• W3014232833 hasConcept C126322002 @default.
• W3014232833 hasConcept C128057223 @default.
• W3014232833 hasConcept C141071460 @default.
• W3014232833 hasConcept C167135981 @default.
• W3014232833 hasConcept C2776760755 @default.
• W3014232833 hasConcept C2779134260 @default.
• W3014232833 hasConcept C2779699572 @default.
• W3014232833 hasConcept C2780252810 @default.
• W3014232833 hasConcept C2781413609 @default.
• W3014232833 hasConcept C2781448352 @default.
• W3014232833 hasConcept C2908647359 @default.
• W3014232833 hasConcept C2911091166 @default.
• W3014232833 hasConcept C71924100 @default.
• W3014232833 hasConcept C99454951 @default.
• W3014232833 hasConceptScore W3014232833C119060515 @default.
• W3014232833 hasConceptScore W3014232833C126322002 @default.
• W3014232833 hasConceptScore W3014232833C128057223 @default.
• W3014232833 hasConceptScore W3014232833C141071460 @default.
• W3014232833 hasConceptScore W3014232833C167135981 @default.
• W3014232833 hasConceptScore W3014232833C2776760755 @default.
• W3014232833 hasConceptScore W3014232833C2779134260 @default.
• W3014232833 hasConceptScore W3014232833C2779699572 @default.
• W3014232833 hasConceptScore W3014232833C2780252810 @default.
• W3014232833 hasConceptScore W3014232833C2781413609 @default.
• W3014232833 hasConceptScore W3014232833C2781448352 @default.
• W3014232833 hasConceptScore W3014232833C2908647359 @default.
• W3014232833 hasConceptScore W3014232833C2911091166 @default.
• W3014232833 hasConceptScore W3014232833C71924100 @default.
• W3014232833 hasConceptScore W3014232833C99454951 @default.
• W3014232833 hasIssue "4" @default.
• W3014232833 hasLocation W30142328331 @default.
• W3014232833 hasOpenAccess W3014232833 @default.
• W3014232833 hasPrimaryLocation W30142328331 @default.
• W3014232833 hasRelatedWork W1890838281 @default.
• W3014232833 hasRelatedWork W1973796431 @default.
• W3014232833 hasRelatedWork W1989117962 @default.
• W3014232833 hasRelatedWork W2085369110 @default.
• W3014232833 hasRelatedWork W2093609645 @default.
• W3014232833 hasRelatedWork W2125886803 @default.
• W3014232833 hasRelatedWork W2318723471 @default.
• W3014232833 hasRelatedWork W3014232833 @default.
• W3014232833 hasRelatedWork W4226023959 @default.
• W3014232833 hasRelatedWork W4240284178 @default.
• W3014232833 hasVolume "39" @default.
• W3014232833 isParatext "false" @default.
• W3014232833 isRetracted "false" @default.
• W3014232833 magId "3014232833" @default.
• W3014232833 workType "article" @default.